PMID- 37202499
OWN - NLM
STAT- MEDLINE
DCOM- 20230614
LR  - 20230614
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 102
IP  - 7
DP  - 2023 Jul
TI  - Outcomes of polatuzumab vedotin-containing regimens in real-world setting of 
      relapsed and or refractory diffuse large B-cell lymphoma patients: a 
      matched-control analysis from the Thai Lymphoma Study Group (TLSG).
PG  - 1887-1895
LID - 10.1007/s00277-023-05273-8 [doi]
AB  - Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging 
      condition to treat, and there is an unmet clinical need for effective therapies. 
      Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate 
      (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL 
      patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, 
      especially in Thailand, are limited. This study aimed to evaluate the efficacy 
      and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. 
      Thirty-five patients who received Pola-based treatment were included in the 
      study, and their data were compared to 180 matched patients who received 
      non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 
      62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, 
      respectively. The median progression-free survival (PFS) and overall survival 
      (OS) were 10.6 months and 12.8 months, respectively. The study found a 
      significantly higher ORR in Pola-based salvage treatments compared to 
      non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also 
      significantly superior in the Pola group, with longer median PFS and OS than the 
      control group. Grades 3-4 adverse events (AEs) were mainly hematological, and 
      they were tolerable. In conclusion, this study provides real-world evidence of 
      the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in 
      Thailand. The results of this study are promising and suggest that Pola-based 
      salvage treatment could be a viable option for R/R DLBCL patients who have 
      limited treatment options.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Rattanathammethee, Thanawat
AU  - Rattanathammethee T
AUID- ORCID: 0000-0003-2731-4889
AD  - Division of Hematology, Department of Internal Medicine, Faculty of Medicine, 
      Chiang Mai University, Chiang Mai, Thailand. thanawat.r@cmu.ac.th.
FAU - Norasetthada, Lalita
AU  - Norasetthada L
AUID- ORCID: 0000-0002-2223-5711
AD  - Division of Hematology, Department of Internal Medicine, Faculty of Medicine, 
      Chiang Mai University, Chiang Mai, Thailand.
FAU - Bunworasate, Udomsak
AU  - Bunworasate U
AUID- ORCID: 0000-0002-8887-4292
AD  - Division of Hematology and Center of Excellence in Translational Hematology, 
      Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
FAU - Wudhikarn, Kitsada
AU  - Wudhikarn K
AUID- ORCID: 0000-0001-9528-8681
AD  - Division of Hematology and Center of Excellence in Translational Hematology, 
      Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
FAU - Julamanee, Jakrawadee
AU  - Julamanee J
AUID- ORCID: 0000-0002-6526-9479
AD  - Hematology Unit, Division of Internal Medicine, Prince of Songkla University, Hat 
      Yai, Songkhla, Thailand.
FAU - Noiperm, Panarat
AU  - Noiperm P
AUID- ORCID: 0000-0002-4967-7237
AD  - Hematology Unit, Division of Internal Medicine, Prince of Songkla University, Hat 
      Yai, Songkhla, Thailand.
FAU - Lanamtieng, Theerin
AU  - Lanamtieng T
AD  - Division of Hematology, Department of Internal Medicine, Faculty of Medicine, 
      Khon Kaen University, Khon Kaen, Thailand.
FAU - Phiphitaporn, Pisa
AU  - Phiphitaporn P
AD  - Division of Hematology, Department of Internal Medicine, Faculty of Medicine, 
      Khon Kaen University, Khon Kaen, Thailand.
FAU - Navinpipat, Manassamon
AU  - Navinpipat M
AD  - Division of Hematology, Department of Medicine, Chulabhorn Hospital, Bangkok, 
      Thailand.
FAU - Kanya, Piyapong
AU  - Kanya P
AUID- ORCID: 0000-0001-8843-4003
AD  - Division of Hematology, Department of Internal Medicine, Chiang Rai Prachanukroh 
      Hospital, Chiang Rai, Thailand.
FAU - Jit-Ueakul, Dusit
AU  - Jit-Ueakul D
AUID- ORCID: 0000-0002-1073-8872
AD  - Division of Hematology, Department of Medicine, Faculty of Medicine, Vajira 
      Hospital, Navamindradhiraj University, Bangkok, Thailand.
FAU - Wongkhantee, Somchai
AU  - Wongkhantee S
AD  - Division of Hematology, Department of Medicine, Khon Kaen Hospital, Khon Kaen, 
      Thailand.
FAU - Suwannathen, Thanongsak
AU  - Suwannathen T
AD  - Division of Hematology, Department of Medicine, Khon Kaen Hospital, Khon Kaen, 
      Thailand.
FAU - Chaloemwong, Juthatip
AU  - Chaloemwong J
AUID- ORCID: 0000-0002-6930-258X
AD  - Division of Hematology, Department of Internal Medicine, Nakornping Hospital, 
      Chiang Mai, Thailand.
FAU - Wong, Peerapon
AU  - Wong P
AD  - Division of Hematology, Department of Medicine, Faculty of Medicine, Naresuan 
      University, Phitsanulok, Thailand.
FAU - Makruasi, Nisa
AU  - Makruasi N
AD  - Division of Hematology, Department of Medicine, Faculty of Medicine, 
      Srinakharinwirot University, Nakhon Nayok, Thailand.
FAU - Khuhapinant, Archrob
AU  - Khuhapinant A
AD  - Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Prayongratana, Kannadit
AU  - Prayongratana K
AD  - Division of Hematology, Department of Internal Medicine, Phramongkutklao Hospital 
      and College of Medicine, Bangkok, Thailand.
FAU - Niparuck, Pimjai
AU  - Niparuck P
AD  - Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Kanitsap, Nonglak
AU  - Kanitsap N
AUID- ORCID: 0000-0002-1231-0212
AD  - Division of Hematology, Department of Medicine, Thammasat University, 
      Pathumthani, Thailand.
FAU - Suwanban, Tawatchai
AU  - Suwanban T
AD  - Division of Hematology, Department of Medicine, Rajavithi Hospital, Bangkok, 
      Thailand.
FAU - Intragumtornchai, Tanin
AU  - Intragumtornchai T
AD  - Division of Hematology and Center of Excellence in Translational Hematology, 
      Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20230518
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - KG6VO684Z6 (polatuzumab vedotin)
RN  - 0 (Immunoconjugates)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Humans
MH  - Southeast Asian People
MH  - Thailand
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - *Immunoconjugates/therapeutic use
MH  - Rituximab
OTO - NOTNLM
OT  - Diffuse large B-cell lymphoma
OT  - Polatuzumab vedotin
OT  - Real-world setting
OT  - Refractory
OT  - Relapse
EDAT- 2023/05/19 01:04
MHDA- 2023/06/14 06:42
CRDT- 2023/05/18 23:21
PHST- 2023/04/07 00:00 [received]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/06/14 06:42 [medline]
PHST- 2023/05/19 01:04 [pubmed]
PHST- 2023/05/18 23:21 [entrez]
AID - 10.1007/s00277-023-05273-8 [pii]
AID - 10.1007/s00277-023-05273-8 [doi]
PST - ppublish
SO  - Ann Hematol. 2023 Jul;102(7):1887-1895. doi: 10.1007/s00277-023-05273-8. Epub 
      2023 May 18.